Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study

Pancreatic ductal adenocarcinoma (PDAC) early diagnosis is  crucial  and new, cheap and user-friendly techniques for biomarker identification  are  needed. “Protein corona” (PC) is emerging a new bio-interface potentially useful in tumor early diagnosis. In a previous investigation, we showed that r...

Full description

Saved in:
Bibliographic Details
Published in:Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2018-09, Vol.18 (6), p.661-665
Main Authors: Caputo, D., Cartillone, M., Cascone, C., Pozzi, D., Digiacomo, L., Palchetti, S., Caracciolo, G., Coppola, R.
Format: Article
Language:English
Subjects:
Adenocarcinoma
Aged
Aged, 80 and over
Biomarkers
Biomarkers for pancreatic ductal adenocarcinoma
Cancer
Carcinoma, Pancreatic Ductal - blood
Carcinoma, Pancreatic Ductal - pathology
Chemotherapy
Data processing
Diagnosis
Early Diagnosis
Electrophoresis, Polyacrylamide Gel
Endoscopy
Family medical history
Female
Gel electrophoresis
Humans
Lipids
Liposomes - blood
Male
Medical imaging
Metastases
Metastasis
Middle Aged
Molecular Weight
Nanoparticles
Nanoparticles - analysis
Nanotechnology
Neoplasm Metastasis
Neoplasm Staging
Pancreatic adenocarcinoma clinical stage
Pancreatic cancer
Pancreatic ductal adenocarcinoma
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - pathology
Pilot Projects
Plasma proteins
Prognosis
Protein corona
Proteins
Sodium lauryl sulfate
Statistical analysis
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic ductal adenocarcinoma (PDAC) early diagnosis is  crucial  and new, cheap and user-friendly techniques for biomarker identification  are  needed. “Protein corona” (PC) is emerging a new bio-interface potentially useful in tumor early diagnosis. In a previous investigation, we showed that relevant differences between the  protein patterns of  PCs formed on lipid NPs after exposure to PDAC and non-cancer plasma  samples exist. To extend that research, We performed this pilot study to investigate the effect of PDAC tumor size and distant metastases on PC composition. Twenty PDACs were clinically staged according to the UICC TNM staging system 8 t h Edition. Collected plasma samples were let to interact with lipid NPs; resulting PCs were characterized by SDS-PAGE. To properly evaluate changes in the PC, the protein intensity profiles were reduced to four regions of molecular weight: < 25 kDa, 25–50 kDa, 50–120 kDa, > 120 kDa.  Data analysis allowed to distinguish T1-T2 cases from T3 and above all from metastatic ones (p 
ISSN:1424-3903
1424-3911
DOI:10.1016/j.pan.2018.06.002